SLC7A5 and neoplasm: Furthermore, the small-molecule LAT1-targeted agent 211At-AAMT offers several advantages over antibody-targeted alpha therapies, including high specificity and affinity, favorable tumor permeability with rapid accumulation, and rapid clearance from most normal tissues [29,30].